Regulated proteolysis by the proteasome involves ~800 enzymes for substrate modification with ubiquitin, of which ~600 are E3 ligases. We report here that E6AP/UBE3A is distinguished from other ubiquitin E3 ligases by having a 12 nM binding site at the proteasome contributed by substrate receptor hRpn10/PSMD4/S5a. Intrinsically disordered by itself, and previously uncharacterized, this domain in hRpn10 locks into a novel well-defined helical structure to form an intermolecular 4-helix bundle with the E6AP AZUL domain, which is unique to this E3. We thus name the hRpn10 AZUL-binding domain RAZUL. We further find in human cells that loss of RAZUL by CRISPR-based gene editing leads to loss of E6AP at the proteasome, where associated ubiquitin is correspondingly reduced, suggesting that E6AP ubiquitinates substrates at or for the proteasome. Altogether, our findings indicate E6AP to be a privileged E3 for the proteasome, with a dedicated, high affinity binding site contributed by hRpn10.
Introduction
The 26S proteasome is a 2.5 MDa complex responsible for regulated protein degradation 1,2 , with substrates typically ubiquitinated by a hierarchical enzymatic cascade 3 . An E1 activating enzyme charges ubiquitin to become a protein modifier and transfers it to an E2 conjugating enzyme which, in concert with an E3 ligating enzyme, subsequently attaches ubiquitin to a substrate. ~600 E3s exist in humans that can either accept the charged ubiquitin for direct transfer to a substrate or serve as a scaffold for ubiquitin transfer from the E2 to a substrate 4-6 .
Following ubiquitination, receptor sites in the proteasome contributed by Rpn1, Rpn10, and Rpn13 recognize ubiquitin directly or the ubiquitin fold of shuttle factor ubiquitin-like (UBL) domains 7-14 ; shuttle factors bind ubiquitinated substrates by one or more ubiquitin-associated (UBA) domain [15] [16] [17] . At the proteasome, ubiquitin chains are hydrolyzed by deubiquitinating enzymes (DUBs) Rpn11 18 , UCHL5/Uch37 19 , and Usp14 20-22 , as the marked substrate is translocated through an ATPase ring for entry into the hollow interior of the proteolytic core particle (CP) 2,23-25 . The integrity of the ubiquitin-proteasome pathway is essential for cellular homeostasis with dysfunction linked to disease, including cancer and neurodegeneration.
Inhibitors of the CP are used to treat hematologic cancers [26] [27] [28] and additional proteasome subunits are being pursued as synergistic targets, including hRpn13 [29] [30] [31] [32] [33] [34] .
Hijacking of ubiquitin E3 ligase E6AP/UBE3A by high risk human papilloma virus E6 oncoprotein contributes to cervical cancer by inducing ubiquitination and in turn degradation of tumor suppressor p53 [35] [36] [37] . Moreover, loss-of-function mutations in E6AP associate with Angelman syndrome [38] [39] [40] and elevated gene dosage with autism spectrum disorders 41 . How aberrant E6AP mechanistically contributes to these neurological diseases is an active area of investigation. It distributes in an isoform-dependent manner between the nucleus and cytosol of neurons 42, 43 and contains an N-terminal Zn-binding AZUL (amino-terminal zinc-binding domain of ubiquitin E3a ligase) domain 44 that binds to Rpn10 in the proteasome 45 , and is required for E6AP nuclear localization 43 . An Angelman syndrome-associated missense mutation in the E6AP HECT domain interferes with E6AP nuclear localization 43 , although the connection between this mutation and the requirement for the AZUL domain is not known. E6AP also stimulates Wnt/β-catenin signaling, a function that requires its ubiquitin ligase activity and interaction with the proteasome, and is disrupted by an autism-linked E6AP mutation 45, 46 .
Although multiple E3 ligases have been reported to associate with the proteasome 22, 47, 48 , no E3 ligase-proteasome complex structure is available, nor has any domain been identified for recruiting an E3 ligase to the proteasome. Here, we identify a novel region at the C-terminal end of hRpn10 that forms a binding site in the proteasome for E6AP. By using biophysical techniques including NMR spectroscopy, we find this region to be disordered when unbound, but upon binding to E6AP, to fold into an independent structural domain characterized by two helices that pack against the E6AP AZUL to form a 4-helix bundle. To test the significance of the E6AP-binding domain, we used gene editing to generate cell lines in which it is deleted and find that this hRpn10 domain contributes E6AP to the proteasome. We unexpectedly find that hRpn10 levels are coupled to E6AP cellular protein levels. Altogether, our data suggest a dual regulatory role for hRpn10 in E6AP function and that through hRpn10, E6AP is a privileged ubiquitin E3 ligase for the proteasome.
Results

Human Rpn10 contains a C-terminal domain that binds E6AP
Rpn10 has an N-terminal von Willebrand factor type A (VWA) domain that assembles into the proteasome and a UIM region for binding ubiquitinated proteins; these domains complete the protein in fungi ( Supplementary Fig. 1a ). In higher eukaryotes, Rpn10 contains an additional conserved ~70 amino acids at the C-terminus ( Fig. 1a and Supplementary Fig. 1a ). We recorded a 2D NMR experiment on 15 N-hRpn10 spanning 196-377, which encompasses the UIM region and uncharacterized C-terminal end. The resulting spectrum indicated that the UIM region, readily identified by our previous assignment of these amino acids 49 , is unperturbed by the additional C-terminal sequence ( Supplementary Fig. 1b ). Ubiquitin addition to demonstrated expected shifting of the UIMs 50,51 but no effect for the unassigned signals ( Supplementary Fig. 1c ). Thus, the additional sequence does not interact with the UIM region, nor does it bind ubiquitin.
To identify proteins that interact directly or in complex with the C-terminal hRpn10 domain, we sub-cloned the region spanning 305-377 in frame with GST, expressed and purified the fusion protein from E. coli, and bound purified GST-hRpn10 to glutathione sepharose resin for incubation with lysates from 293T (human embryonic kidney epithelial) or HCT116 (colorectal carcinoma) cells. After washing, resin-bound proteins were separated by SDS-PAGE, eluted from the gel, digested with trypsin, and analysed by mass spectrometry; parallel experiments were done with GST protein as a control. The only hit identified for either 293T or HCT116 lysate was E6AP ( Supplementary Fig. 2a ).
To test whether E6AP binds to the hRpn10 C-terminal region directly, we incubated full-length E6AP with Ni-NTA resin pre-bound to His-hRpn10 full-length , His-hRpn10 . hRpn10 full-length and hRpn10 bound E6AP, whereas hRpn10 196-306 did not (Fig. 1b ). We next added unlabelled AZUL to 15 N-hRpn10 and monitored the effect by 2D NMR to find hRpn10 signals shifted (Fig. 1c ), indicating binding. We assigned both the free and AZUL-bound state, as described in Methods, and quantified the changes to find D327-M356 perturbed ( Supplementary Fig. 2b ). Analogous experiments with unlabelled hRpn10 and 15 N-6 E6AP AZUL , aided by previous assignments 44 , indicated residues in both AZUL helices to be significantly shifted by hRpn10 addition ( Supplementary Fig. 2c and 2d ). Altogether, these experiments indicate direct binding between E6AP AZUL and hRpn10 , consistent with recent publications implicating AZUL and hRpn10 to E6AP interaction with the proteasome 43, 45 .
To assess the strength of hRpn10 :AZUL interaction, we used isothermal titration calorimetry (ITC) with the AZUL added incrementally to hRpn10 305-377 ; a K d value of 11.6 + 3.3 nM was measured ( Fig. 1d and Supplementary Fig. 2e ), indicating similar strength to hRpn13 interaction with the proteasome 52, 53 . Surface plasmon resonance (SPR) similarly revealed a K d value of 8.1 + 1.4 nM for GST-hRpn10 binding to AZUL ( Fig. 1d and Supplementary Fig.   2f ).
To test whether the hRpn10 C-terminal region is required for interaction with endogenous E6AP in cells, lysates from HCT116 cells expressing either myc-hRpn10 full-length or myc-hRpn10 were subjected to immunoprecipitation with anti-myc nanobody-coupled agarose. Coimmunoprecipitation of E6AP was observed with full-length but not truncated hRpn10 (Fig. 1e ).
We further co-expressed HA-E6AP with either hRpn10 construct and immunoprecipitated E6AP with anti-HA antibodies to find co-immunoprecipitation of full-length, but not truncated, hRpn10 ( Fig. 1f ).
Altogether, these data indicate that the E6AP AZUL is a strong interaction partner of hRpn10 and we henceforth refer to this domain in Rpn10 as RAZUL (Rpn10 AZUL binding domain, Fig. 1g ).
E6AP protein levels depend on hRpn10
To test the significance of the RAZUL:AZUL interaction, we considered generating a full hRpn10 knockout cell line. However, we found that hRpn10 knockdown by siRNA resulted in loss of proteasome components hRpn8 and hRpn11 associating with proteasome ATPase Rpt3 (Fig.   1a ), consistent with an early report that Rpn10 is necessary for base-lid interactions in the yeast proteasome 54 . To avoid such proteasome defects, we utilized CRISPR/Cas9 to generate a cell line in which hRpn10 lacks RAZUL but retains intact VWA and UIMs (see Methods). Deletion of RAZUL was assayed by immunoblotting, as demonstrated for clones 13 and 14 (Fig. 2b) ; we henceforth refer to these cell lines as ΔRAZUL.
Lower levels of truncated hRpn10 were consistently observed in ΔRAZUL cells compared to the full-length protein in WT cells, with clone 14 producing less protein than clone 13 ( Fig. 2a , second panel). Unexpectedly, E6AP levels correlated with hRpn10 ΔRAZUL levels ( Fig. 2a, top panel). To test whether the reduced protein levels are due to protein degradation, WT and ΔRAZUL cells were treated with 10 μM MG132 for four hours to inhibit the proteasome. As expected, MG132 treatment caused ubiquitinated proteins to accumulate in both cell lysates ( Supplementary Fig. 3 , third panel). No increase was observed however for either hRpn10 ΔRAZUL or E6AP, nor were higher molecular weight bands apparent ( Supplementary Fig. 3 ).
We assayed E6AP levels in cells with siRNA knockdown of hRpn10 to similarly find direct correlation ( Fig. 2c ). Loss of E6AP by siRNA treatment however had no effect on hRpn10 levels ( Fig. 2d ).
We attempted to rescue E6AP levels in ΔRAZUL cells (clone 14) by expressing hRpn10 full-length or ΔRAZUL protein; however, no increase in endogenous E6AP protein was observed for either condition ( Fig. 2e ). We further interrogated this effect in WT or ΔRAZUL cells by expressing E6AP and hRpn10 constructs either independently or in combination. Exogenous expression of E6AP was reduced in ΔRAZUL (clone 13) compared to WT cells (Fig. 2f , lane 2 versus lane 4).
Exogenous E6AP levels were boosted however in ΔRAZUL cells (clone 13) when either truncated (lane 5) or full-length (lane 6) hRpn10 was co-transfected with E6AP ( Fig. 2f) ; thus the effect is not dependent on the RAZUL:AZUL interaction, however full-length hRpn10 had a stronger effect on E6AP levels than truncated hRpn10. Altogether, these data link hRpn10 to E6AP production with possible spatial or temporal regulation that allows rescue of E6AP when the two proteins are co-expressed.
E6AP AZUL binds to hRpn10 RAZUL at the proteasome
We used ΔRAZUL cells to test whether the hRpn10 RAZUL recruits E6AP to the proteasome, boosting hRpn10 levels by transient transfection. Proteasomes from lysates of WT and ΔRAZUL cells (clone 13) expressing myc-tagged hRpn10 full-length or ΔRAZUL protein were immunoprecipitated with Rpt3 antibodies and immunoprobed for hRpn10, E6AP, or proteasome component hRpn2 (as a control). E6AP co-immunoprecipitated with proteasomes from WT (Fig.   3a , lane 2 and 3), but not ΔRAZUL (Fig. 3a , lane 5) cells. Expression of full-length (lane 7) but not RAZUL-truncated hRpn10 (lane 6) resulted in observable E6AP co-immunoprecipitation with proteasomes isolated from ΔRAZUL cells (Fig. 3a) ; we attribute the lower amounts of E6AP coimmunoprecipitated with proteasomes of hRpn10 full-length -expressing ΔRAZUL cells to the reduced abundance of endogenous E6AP in this cell line, as described above ( Fig. 2a ). This experiment indicates that the hRpn10 RAZUL contributes E6AP to the proteasome.
We further tested whether RAZUL could compete with the proteasome for E6AP binding.
Proteasomes immunoprecipitated from HCT116 cells over-expressing myc-hRpn10 RAZUL were immunoprobed for E6AP and compared to empty vector transfected cells and an IgG control. Expression of RAZUL caused E6AP to be lost from the proteasome (Fig. 3b ).
To test the impact of E6AP at the proteasome, Rpt3 immunoprecipitates from lysates of cells transfected with a scrambled control or siRNA against E6AP were immunoprobed for ubiquitin.
While no major change in total ubiquitin levels was observed at the level of whole cell extract (WCE), a reduction in bulk ubiquitin was apparent at the proteasome following E6AP loss, particularly for higher molecular weight species (Fig. 3c ).
To test directly whether the RAZUL:AZUL interaction observed for the isolated domain complex is maintained in the intact proteasome, we added equimolar 13 C-AZUL to RAZUL or 26S proteasome ( Supplementary Fig. 4a ) and acquired a 1D 13 C-edited, 1 H NMR experiment for comparison to free 13 C-AZUL. Binding to RAZUL induced shifting ( Supplementary Fig. 4b , middle vs bottom panel), as exemplified by methyl groups of M24 and M63 ( Fig. 3d, left panel) and I33, L75, and L82 ( Fig. 3d , right panel). The spectrum acquired with proteasome added closely mimicked that with only RAZUL added ( Fig. 3d and Supplementary Fig. 4b ), indicating that AZUL binding to RAZUL occurs identically at the proteasome.
E6AP induces helicity in RAZUL
We used NMR to solve the structure of the RAZUL:AZUL complex, as described previously 55, 56 and in Methods, with the data summarized in Table 1 . We recorded 13 C-half-filtered NOESY experiments on samples of the complex with one protein 13 C labeled and the other unlabeled to measure unambiguous intermolecular interactions ( Supplementary Fig. 5 ). Altogether, 217
interactions between AZUL and RAZUL were identified (Table 1) . The 15 lowest energy structures converged with a root-mean-square deviation (r.m.s.d.) of 0.59 Å (Fig. 4a ).
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Unbound AZUL is comprised of two helices (H1 and H2) and a Zn finger 44 and this architecture is maintained in the RAZUL-bound state, with a backbone r.m.s.d. between the free and complexed structures of 1.3 Å ( Supplementary Fig. 6a ). RAZUL binds the AZUL helices from the opposite direction compared to the Zn finger ( Fig. 4b ). In this complex, two α-helices are formed in RAZUL that span P332-N341 (α1) and E350-S361 (α2), with an angle of 158.5º between the two helical axes. Directly N-terminal to RAZUL α1 is a single turn of a 3 10 -helix that spans V328-Q330 ( Fig. 4b ). We submitted the atomic coordinates of the RAZUL:AZUL complex to the Dali server 57 to find no similarities with either the AZUL or RAZUL domain, indicating that RAZUL is unique and not previously described.
Comparisons of our NMR data acquired on free and AZUL-bound RAZUL indicate that RAZUL acquires helicity upon binding to AZUL. Carbonyl and Cα values when compared to random coil taking into account amino acid type yields a chemical shift index (CSI) that informs on secondary structure; these values shift to reflect greater helicity for RAZUL when bound to AZUL ( Fig. 4c and Supplementary Fig. 6b ). Moreover, intramolecular interactions characteristic of helicity were observed following AZUL addition, but not for free RAZUL ( Supplementary Fig.   6c and 6d). Overall, our NMR data indicate that RAZUL switches from a poorly ordered state to a well-defined helical state following AZUL binding. We interrogated this finding further by circular dichroism (CD) spectroscopy, as done previously for Rap80 58,59 . CD measurements indicated 7 and 46% helicity respectively for unbound RAZUL (blue) and AZUL (green), and a theoretical spectrum (gray dashed line) for the mixture with markedly less spectral features of helicity compared to the recorded experimental spectrum (orange, Fig. 4d ). 35% overall helicity is indicated from the experimental CD data recorded on the complex, consistent with the 36% helicity determined by NMR (Fig. 4b ). The AZUL secondary structure is unaltered by binding to 1 2 Fig. 7a ), as expected from the structure ( Fig. 4a and 4b ). Y326 phosphorylation of hRpn10 reduced affinity for AZUL 10-fold ( Fig. 5f and Supplementary Fig. 7b ). We next tested the importance of the hydrogen bond contributed by Y326 by replacing this amino acid with phenylalanine. E6AP co-immunoprecipitation with the proteasome is reduced in ΔRAZUL cells expressing hRpn10 Y326F compared to those expressing the wild-type protein (Fig. 5g , lane 8 versus 7). We also found that losing the unstructured C-terminal region (365-377) from hRpn10 had no effect on E6AP co-immunoprecipitation with proteasomes by expressing hRpn10 in ΔRAZUL cells (Fig. 5g, lane 9 ). This finding is consistent with the ITC data indicating equivalent AZUL affinity for hRpn10 (Fig. 5f ).
Altogether, these data indicate that the hRpn10 RAZUL forms an independent structural domain that contributes E6AP to the proteasome.
Discussion
~600 ubiquitin E3 ligases exist in humans. We report here that proteasome substrate receptor hRpn10 evolved a 12 nM affinity binding domain for recruiting E6AP to the proteasome through the N-terminal AZUL domain, which is a unique feature of E6AP. This finding provides new foundational knowledge that impacts future studies aimed at addressing the role of E6AP in cervical cancer, Angelman syndrome, and autism. Our results also redefine the current models of the 26S proteasome to include a dedicated binding domain in hRpn10 that has until now been uncharacterized despite the discovery of Rpn10 as a proteasome substrate receptor over 2.5 decades ago 61 . This domain may have remained elusive in earlier studies in part due to its disordered state when unbound and its absence in fungi.
The induced folding of RAZUL upon binding to E6AP is similar to the coupled folding reported in previous studies 62,63 , such as the N-terminal transactivation (TAD) domain of p53, which exchanges between a disordered and partially helical conformation when unbound 64-66 and forms a stable amphipathic α-helix when complexed with the E3 ligase Mdm2 67 . Increasing intrinsic helicity of the p53 TAD domain yields stronger binding to Mdm2 in vitro and in cells 68 , suggesting that RAZUL could potentially be engineered to increase E6AP occupancy at the proteasome in future work or alternatively for E6AP targeting.
In contrast to hRpn10, the other two proteasome receptors, Rpn1 and Rpn13, contribute binding sites for DUBs 11, 22, [69] [70] [71] . Proximity between substrate receptors and DUBs is no doubt conducive to ubiquitin recycling and the chain removal needed for substrate translocation into the proteolytic CP. Although it does not contribute a DUB-binding site, Rpn10 is proximal to the proteasomal DUB Rpn11 72,73 . Why would the proteasome be benefitted by physically linking a substrate receptor to a ubiquitin E3 ligase? One possibility would be to regulate proteasome subunits, considering that E6AP is reported to ubiquitinate proteasome components, including Rpn10 74,75 , albeit at low levels [74] [75] [76] . Rpn10 is also ubiquitinated in yeast, which is proposed to regulate its presence at the proteasome 77,78 and affinity for ubiquitinated proteins 79 ; however, yeast lack both RAZUL and E6AP ( Supplementary Fig. 1a ) suggesting Rpn10 ubiquitination has redundant mechanisms or is independent of E6AP. In agreement with this, we found no evidence of altered levels or a molecular weight increase indicative of ubiquitination for hRpn10 following E6AP knockdown in HCT116 cells ( Fig. 2d) , although it remains possible that such activity requires induction by a specific cellular event or is cell type specific.
Another possibility is that E6AP localization to the proteasome via hRpn10 RAZUL serves in the broader cellular context to allow ubiquitin chains to be remodelled for more efficient degradation, as has been previously proposed for UBE3C/HUL5 80 . UBE3C was the first reported ubiquitin ligase to physically interact with the proteasome, with its binding site likely somewhere in the proteasome base subcomplex 80,81 ; however, its specific binding site has yet to be elucidated, and its recruitment to the proteasome appears to be assisted by structurally impaired substrate 76 .
We propose that reconfiguration of ubiquitin chains by E6AP enables more efficient degradation of proteasome substrates. Various models have been proposed to explain how different chain lengths/linkages affect the degradation rate of proteins, with multiple short ubiquitin chains shown to have higher efficiency of degradation than a single long chain 82 . Multiple ubiquitin chains on a substrate may more readily enable multiplexed points of contact with receptor sites and associated/nearby DUBs around the degradation channel and thereby enable more efficient substrate translocation. E6AP interacting with the proteasome through the Rpn10 RAZUL would be ideally situated to modify substrates in this manner, with proximity to substrates recruited by the Rpn10 UIMs or associated shuttle factors. This model is supported by our finding that E6AP knockdown reduces ubiquitin co-immunoprecipitating with the proteasome, despite largely unchanged ubiquitin levels in the whole cell extract ( Fig. 3c ). It has also been demonstrated that ubiquitin chains consisting of K11/K48 branched chains are more efficiently degraded by the proteasome than K11-linked chains 83 . E6AP is known to catalyze K48 linkages, however its specificity has not been studied extensively. It is possible that E6AP could add K48-linked ubiquitin (or other linkages, as yet to be determined) to existing K11-linked chains, in order to enhance degradation of substrates.
As human E6AP isoform 3 localizes to the nucleus in an hRpn10-and AZUL-dependent manner 43 , it may be that the E6AP's function in the nucleus is primarily related to its association with hRpn10. By contrast, the decreased affinity for E6AP when RAZUL is phosphorylated at Y326 may imply that certain cellular contexts require less E6AP associated with the 1 5 proteasome. For example, although we were unable to detect evidence of Y326 phosphorylation in HCT116 cells (data not shown), the identification of Y326 phosphorylation in Jukat cells (immortalized human T lymphocyte) may be significant given that immune cell activation is tightly regulated by ubiquitination 84 . E6AP has been reported to interact with Lck and Blk 85 , which are immune cell-specific tyrosine kinases at the plasma membrane involved in T cell receptor (TCR) or B cell antigen receptor (BCR) mediated activation, respectively. It is conceivable that upon TCR or BCR activation, an immune cell-specific kinase is recruited to hRpn10 via E6AP, and that subsequent phosphorylation of hRpn10 leads to reduction of E6AP at the proteasome, and in turn, delayed degradation of receptor components, allowing an elongated timeframe of activation. This mode of regulation could allow a fine-tuning of receptor activation by regulating E6AP activity at the proteasome in a very specific cellular location and context.
While future studies will elucidate the intricacies of E6AP function at the proteasome, our findings provide insight into the uniqueness of E6AP as an E3 ligase with a dedicated binding site at the proteasome and protein abundance that correlates with proteasome substrate receptor hRpn10. Our finding that E6AP binds a domain of hRpn10 not present in yeast in combination with our discovery that E6AP levels depend on hRpn10 suggests that these two proteins evolved together to have linked functions, underscoring the importance of E6AP at the proteasome. These results provide a new foundation towards understanding the role of E6AP in its associated disease states.
Methods details
Protein sample preparation for biophysics experiments
Human Rpn10 305-377 or its amino acid substituted variants were sub-cloned into pGEX-6P-3 vector and expressed in Escherichia coli strain Rosetta 2 (DE3) as fusion proteins with Nterminal glutathione S-transferase (GST) and a PreScission protease cleavage site. Cells were grown at 37°C to OD 600 of 0.5 -0.6 and protein expression induced overnight at 17°C by addition of 0.4 mM IPTG. The cells were frozen in liquid nitrogen and stored at -80°C for ~4 hrs, followed by resuspension in buffer 1 (50 mM Tris at pH 7.2, 300 mM NaCl, 5 mM DTT) supplemented with protease inhibitor cocktail tablets (Roche Diagnostics). Cells were lysed by sonication and spun down at 27,000 g for 30 min, after which the supernatant was incubated with pre-washed glutathione sepharose resin for 3 hrs. After extensive washing in buffer 1, hRpn10 305-377 or its amino acid substituted variants were either separated from GST and the resin by cleaving with PreScission protease in buffer 2 (10 mM MOPS at pH 6.5, 50 mM NaCl, 5 mM DTT, 10 μM zinc sulphate), or eluted from the resin with the GST-tag intact by using buffer 3 (50 mM Tris at pH 7.2, 50 mM NaCl, 5 mM DTT, 20 mM glutathione). Further purification was achieved by size exclusion chromatography on an FPLC system ÄKTA pure (GE Healthcare) using a HiLoad 16/600 Superdex 75 (for samples with no GST-tag) or Superdex 200 (for GSTtagged protein) prep grade column in buffer 2 or 3. E6AP 24-87 was sub-cloned into the pET28a vector and expressed in Escherichia coli strain BL21 (DE3) as a fusion protein with an N-terminal polyhistidine tag and a thrombin cleavage site. Cells were grown at 37°C to OD 600 of 0.5 -0.6 and protein expression induced at 17°C overnight by 0.4 mM IPTG. At the time of induction, zinc sulphate was added to a final concentration of 20 μM. The cells were frozen in liquid nitrogen and stored at -80°C for ~4 hrs, followed by resuspension in buffer 4 (10 mM MOPS at pH 7.2, 300 mM NaCl, 5 mM 2 mercaptoethanol, 10 uM zinc sulphate) supplemented with protease inhibitor cocktail tablets (Roche Diagnostics). Cells were lysed by sonication and spun down at 27,000 g for 30 min. The supernatant was incubated with pre-washed Ni-NTA agarose resin (Qiagen) for 1 hr. After extensive washing in buffer 4, E6AP 24-87 was separated from the His-tag and the resin by cleaving with thrombin in buffer 5 (10 mM MOPS at pH 6.5, 50 mM NaCl, 5 mM 2 mercaptoethanol, 10 μM zinc sulphate). Further purification was achieved by size exclusion chromatography on an FPLC system ÄKTA pure (GE Healthcare) using a HiLoad 16/600 Superdex 75 prep grade column in buffer 5. hRpn10 196-377 was sub-cloned into the pET14b vector with an N-terminal polyhistidine tag and a thrombin cleavage site. pET11d/His 6 -hRpn10 full-length is a gift from Dr. Fumio Hanaoka.
pET26b/His 10 -hRpn10 196-306 was reported previously 12, 50 . N-terminal His-tagged hRpn10 full-length , hRpn10 were expressed from Escherichia coli strain BL21 (DE3) and purified in an identical manner as N-terminal His-tagged E6AP 24-87 , but eluted from the resin with the His-tag intact by using elution buffer 6 (10 mM MOPS at pH 7.2, 50 mM NaCl, 5 mM 2 mercaptoethanol, and 250 mM imidazole), and further purified by size exclusion chromatography on an FPLC system ÄKTA pure (GE Healthcare) with a HiLoad 16/600 Superdex 75 prep grade column in buffer 5. 15 N ammonium chloride, 13 C glucose, and 2 H 2 O were used for isotope labeling. All NMR 1 8 for 2 min for sequences containing no Cys or Asp. All deprotection cycles after Asp and Cys were conducted at room temperature to avoid racemization and aspartimide formation. Low loading Rink Amide MBHA resin (Merck) was used for the synthesis of amidated peptides and Wang resins were used for the synthesis of peptides with free carboxy-termini. The peptides were cleaved from the resin and deprotected with a mixture of 90.0% (v/v) trifluoroacetic acid (TFA) with 2.5% water, 2.5% triisopropyl-silane, 2.5% 2,2′-(ethylenedioxy)diethanethiol and 5% thioanisol. Peptides were purified on a preparative (25 mm x 250 mm) Atlantis C3 reverse phase column (Agilent Technologies) in a 90 min gradient of 0.1% (v/v) trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile, with a 10 mL/min flow rate. The fractions containing peptides were analyzed on an Agilent 6100 LC/MS spectrometer with the use of a Zorbax 300SB-C3 PoroShell column and a gradient of 5% acetic acid in water and acetonitrile.
Fractions that were more than 95% pure were combined and freeze dried.
GST-pulldown experiment and sample preparation for mass spectrometry
HCT116 and 293T cells were purchased from American Type Culture Collection (ATCC CCL-247 and CRL-3216). 293T cells were grown in DMEM (GlutaMAX TM -1 with 4.5 g/L D-glucose and without sodium pyruvate, Thermo Fisher Scientific) and HCT116 cells were grown in McCoy's 5A modified medium (ATCC 30-2007) , with both media supplemented with 10% fetal bovine serum (Atlanta Biologicals, Inc. S12450). Cells were grown in a 37°C humidified atmosphere of 5% CO 2 . Cells were collected, washed twice with PBS, and lysed in 1% Triton-TBS buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1 mM PMSF), supplemented with protease inhibitor cocktail (Roche Diagnostics). Total protein concentration in the lysate was determined by a Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific 23225). 2 nmol of purified GST-tagged hRpn10 or GST protein (Thermo Scientific 20237) was added to 20 μL of pre-washed glutathione sepharose resin for 3 hrs, washed once with buffer 7 (50 mM Tris at pH 7.5, 150 mM NaCl, 2 mM DTT, 0.5% (v/v) Triton-X100, 10 μM zinc sulphate), and the resin next incubated with 1.2 mL of cell lysate for 3 hrs. Unbound protein was removed by washing three times in buffer 8 (20 mM Tris at pH 7.6, 150 mM NaCl, 2 mM DTT, 10% glycerol, 10 μM zinc sulphate), after which resin-bound proteins were eluted, subjected to electrophoresis on a 4-12% NuPAGE Bis-Tris gel (Thermo Fisher Scientific NP0322), and visualized by Coomasie staining.
For each of the six lanes (GST-hRpn10 or GST protein incubated with 293T or HCT116 cell lysate), the region above 39 kDa was cut into 12 bands that were placed individually into 1.5 mL eppendorf tubes. Each gel band was then further cut into small pieces and destained using 50% acetonitrile/25 mM NH 4 HCO 3 at pH 8. After removal of the organic solvent, gel pieces were dried by vacuum centrifugation for 1 hr. Trypsin (20 ng/µL) in 25 mM NH 4 HCO 3 at pH 8, was added to each sample (50 µL) and incubated on ice for 1 hr. 25 mM ammonium bicarbonate was added to completely saturate the bands for overnight incubation at 37°C. Peptides were extracted in 70% acetonitrile and 5% formic acid using bath sonication and supernatant solutions were dried in a speed vacuum. Samples were desalted utilizing Pierce C18 spin columns (Thermo Fisher Scientific), dried, and resuspended in 0.1% TFA prior to mass spectrometry analysis.
Nanoflow Reversed Phase Liquid Chromatography (nanoRPLC)-Tandem Mass
Spectrometry
Peptides were analyzed on a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific). The desalted tryptic peptide was loaded onto an Acclaim PepMap 100 C18 LC column (Thermo Fisher Scientific) utilizing a Thermo Easy nLC 1000 LC system (Thermo Fisher Scientific) connected to the Q Exactive mass spectrometer. The peptides were eluted with a 5-48% gradient of acetonitrile with 0.1% formic acid over 55 min with a flow rate of 2 0 300 nL/min. The raw MS data was collected and analyzed in Proteome Discoverer 2.2 (Thermo Fisher Scientific) with Sequest HT software and was searched against the Human Proteome database.
His pull-down assays
His pull-down assays were performed as described previously 11, 87 . Briefly, 2 nmol of purified His-tagged hRpn10 full-length , hRpn10 was added to 20 μL of pre-washed Ni-NTA agarose resin (QIAGEN) for 2 hrs and washed once with buffer 5. The resin was then incubated with 200 pmol of E6AP (UBPBio K1411) for 1 hr and unbound protein removed by extensive washing with buffer 5. Resin-bound proteins were eluted and subjected to SDS-PAGE followed by visualization with Coomasie staining.
ITC and SPR binding affinity experiments
ITC was performed at 25°C on a MicroCal iTC200 system. hRpn10 305-377 , E6AP 24-87 , and hRpn10 322-366 peptide without or with Y326 phosphorylated were dialyzed extensively against buffer 2. Eighteen 2.1 μ L aliquots of 0.462 mM E6AP 24-87 were injected at 1000 rpm into a calorimeter cell (volume 200.7 μ L) that contained 0.0405 mM hRpn10 . For measuring interaction between hRpn10 322-366 peptides and E6AP 24-87 , eighteen 2.1 μ L aliquots of 0.110 mM E6AP 24-87 were injected at 1000 rpm into a calorimeter cell (volume 200.7 μ L) that contained 0.01 mM hRpn10 322-366 without or with Y326 phosphorylated. Blank experiments were performed by replacing protein samples with buffer and this blank data was subtracted from the experimental data during analysis. The integrated interaction heat values were normalized as a function of the molar ratio of E6AP 24-87 to hRpn10 or to hRpn10 322-366 peptides, and the data were fit with MicroCal Origin 7.0 software. Binding was assumed to be at one site to yield the binding affinity Ka (1/Kd), stoichiometry, and other thermodynamic parameters. 1 Surface plasmon resonance experiments were recorded for GST-tagged hRpn10 and E6AP 24-87 with a Biacore T200 system (GE Healthcare). Utilizing the GST capture kit, 4000 RU of anti-GST antibody was covalently immobilized on a CM5 chip via amine coupling. GSTtagged hRpn10 was then added to FC2 to a final response of 800 RU. As a negative control, GST was added to FC1 to the same response. E6AP 24-87 was prepared in degassed, filtered HBS-P+ (GE Healthcare) buffer with 10 μM zinc sulphate. Single cycle kinetic experiments were performed using five injections (30 µL/min) of increasing concentration of protein (5-250 nM) passed over the sensor chip for 150 sec association, followed by a 420 sec dissociation. The experiments were repeated in triplicate. Buffer and reference subtracted kinetic constants (k on and k off ) and binding affinities (K d ) were determined utilizing the Biacore T200 evaluation software (GE Healthcare).
CD experiments
Far-UV range CD spectra (240-190 nm) of 10 μM hRpn10 305-377 , 10 μM E6AP 24-87 , the mixture of 10 μM hRpn10 305-377 and 10 μM E6AP 24-87 , and buffer 9 (10 mM MOPS, 10 mM NaCl, 10 mM DTT, 10 μM zinc sulphate at pH 6.5, as a control) were recorded on a Jasco J-1500 circular dichroism spectrometer (Tokio, Japan) using a quartz cuvette with 1.0 mm path length and temperature controlled at 25 ± 0.1°C. All spectra were collected continuously at a scan speed of 20 nm/min and averaged over accumulation of three spectra. The buffer spectrum was subtracted from the protein spectra during data analyses. The molar ellipticity θ (in deg cm 2 dmol −1 ) was calculated from the measured machine units m° in millidegrees at wavelength λ using the Equation 1.
C is the concentration of the sample in mol L -1 and L is the path length of the cell (cm). Table S1 . HCT116 cells were co-transfected with the Cas9-2A-mCerulean constructs in combination with the donor construct. Two days post transfection, cells were split into a fresh 6-well plate and grown in media with puromycin for two weeks. A few cell colonies were visible after two weeks that were picked using sterile tips and added to a 24-well plate with fresh media. Individual clones were then analyzed by immunoblotting using hRpn10 antibody to identify clones containing the truncation. Clones 13 and 14 were selected based on this analysis, and genomic DNA isolated from clones 13 and 14 were used in PCR amplification using primers outside the homology arms. PCR fragments of the expected size were generated, and PCR using one primer outside the homology arm and one to puromycin validated insertion of the donor sequence. PCR-amplified genomic DNA was cloned into the pCR™4-TOPO® vector using a TOPO™ TA Cloning™ Kit (Life Technologies K457501) and sequence verified.
Cell lysis and immunoprecipitations
All cells were washed twice in cold PBS (Thermo Fisher Scientific) prior to harvesting. Cells used for Rpt3 IP were harvested on ice in 1% Triton X-100 buffer (1% Triton X-100, 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM PMSF, 5 μg/mL Pepstatin A, and Roche EDTA-free protease inhibitor cocktail). Cell extracts were centrifuged for 15 min at 4°C and 20,000g, and the supernatant was isolated. IPs were performed overnight at 4°C with 1-1.5 mg total protein lysate, using 4 μL Rpt3 antibody (abcam ab140515) per condition. Protein G sepharose beads (GE healthcare 17-0618-01) were added to IPs for 3 hrs, and precipitates were washed 5-7 times with 1% Triton X-100 buffer. Immune complexes were heated to 95°C for 10 min in denaturing sample buffer prior to subjection to SDS-PAGE.
Cells used for myc-trap IPs were harvested on ice in 0.5% NP-40 lysis buffer (0.5% Nonidet P-40, 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM PMSF, 5 μg/mL Pepstatin A, 10 mM sodium pyrophosphate, 10 mM NaF, 1 mM Na 3 VO 4 , and Roche EDTA-free protease inhibitor cocktail).
Cell extracts were placed on ice for 30 min with extensive pipetting every 10 min. Extracts were centrifuged at 20,000g for 30 min at 4°C. Supernatants were diluted 1:1 with myc-trap dilution/wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM PMSF, 5 μg/mL Pepstatin A, 10 mM sodium pyrophosphate, 10 mM NaF, 1 mM Na 3 VO 4 , and Roche EDTA-free protease inhibitor cocktail), and 1-1.5 mg total protein lysate was incubated with 25 μL myc-trap agarose (nanobody coupled) beads (chromotek) overnight at 4°C. Nanobody-myc complexes were washed 5 times with myc-trap dilution/wash buffer and heated to 95°C for 10 min in denaturing sample buffer prior to subjection to SDS-PAGE.
In experiments not involving immunoprecipitation, cells were either harvested in 1% Triton X-100 buffer or 1% NP-40 buffer (1% Nonidet P-40, 25 mM Tris pH 7.2, 137 mM NaCl, 10% glycerol, 1 mM DTT, 5 mg/mL Pepstatin A, 1 mM PMSF, and Roche protease inhibitor cocktail).
Lysates were centrifuged at 20,000g and 4°C for 15 min and supernatants were isolated for immunoblotting. 
SDS-PAGE, immunoblots, and antibodies
NMR samples and experiments
Three NMR samples were prepared, including 1) 0.5 mM 15 N, 13 C, 35% 2 H-labeled Rpn10 mixed with unlabeled E6AP 24-87 at 1.5-fold molar excess; 2) 0.5 mM 15 N, 13 
Structure calculation of the hRpn10 RAZUL: E6AP AZUL complex
XPLOR-NIH 2.50 101 was used on a Linux operating system to solve the complexed structure by using NOE and hydrogen bond constraints as well as backbone φ and ψ torsion angle constraints derived from TALOS+ 98 (Table 1) . Hydrogen bonds were generated by using secondary structure assignments and NOE connectivities with defined distances from the acceptor oxygen to the donor hydrogen and nitrogen of 1.8-2.1 Å and 2.5-2.9 Å, respectively.
Hydrogen bonds restraints were not included in the initial calculation, but were in the final round of structure calculations. When calculating the structures of hRpn10 RAZUL:E6AP AZUL, intermolecular distance constraints determined from the 3D 13 C-half-filtered NOESY experiments were used, in addition to intramolecular constraints for hRpn10 RAZUL and E6AP
AZUL that were generated from 15 N or 13 C NOESY spectra acquired on the complexes (Table   1 ). The complexed structures were calculated from 50 linear starting structures of hRpn10 RAZUL and E6AP AZUL molecules, which were subjected to 2,000 steps of initial energy minimization to ensure full spatial sampling and appropriate coordinate geometry. The structures were next confined according to the inputted data by subjecting them to 55,000 simulated annealing steps of 0.005 ps at 3,000 K, followed by 5,000 cooling steps of 0.005 ps. (blue), AZUL (green), and the mixture (orange). The theoretical sum spectrum based on free values (grey) is displayed, with a table listing predicted helicity and schematic depicting the effect of AZUL on RAZUL structure. 
Figure Legends
